Who are AbbVie's decision-makers?

Robert A. Michael became CEO on July 1, 2024, and was elevated to Chairman of the Board effective July 1, 2025, completing a leadership transition from founding CEO Richard Gonzalez. Michael spent his entire post-spin career at AbbVie: he built the company's first financial planning organization in 2013, then progressed through commercial, financial, and operational roles before serving as President and COO from approximately 2021 to mid-2024. His predecessor, Richard Gonzalez, was an Abbott Labs veteran of more than 30 years and served as AbbVie's founding CEO from 2013 to 2024, overseeing both the Pharmacyclics acquisition and the transformative Allergan deal.

The current EVP layer covers every major functional domain. Scott Reents (CFO, since 2018) manages capital allocation and investor relations. Roopal Thakkar, M.D. (EVP R&D and CSO, appointed July 2024) leads more than 14,000 R&D team members across six global centers of excellence in the U.S., Germany, and Japan, succeeding Thomas Hudson upon his retirement. Azita Saleki-Gerhardt (EVP COO, Abbott/AbbVie since 1993) manages a vast global manufacturing and supply chain operation. Nicholas Donoghoe (EVP CBSO) leads business development, corporate strategy, and Business Technology Operations. Perry Siatis (EVP General Counsel, since October 2022) oversees legal and compliance globally. Jeffrey Stewart (EVP CCO, since 2019) leads the global commercial organization.

For large enterprise technology and services purchases, the effective buying committee at AbbVie runs through three key leaders. Nicholas Donoghoe (CBSO) controls business development, corporate strategy, and Business Technology Operations — meaning he owns the strategic technology agenda and drives large-platform decisions such as the enterprise-wide Salesforce Life Sciences Cloud deployment. Azita Saleki-Gerhardt (COO) governs manufacturing ERP, quality systems, and supply chain technology, making her critical for any vendor in clinical operations, manufacturing execution systems, or logistics platforms. Scott Reents (CFO) controls enterprise budget approval and is the final financial signatory on deals exceeding normal operational thresholds.

At the commercial layer, Jeffrey Stewart (CCO) and his commercial analytics and market access teams determine CRM, sales force automation, and HCP engagement platform decisions. For R&D and clinical technology vendors, Roopal Thakkar (CSO) sets the investment agenda in data science, AI-driven drug discovery, real-world evidence, and clinical trial management systems — a role underscored by AbbVie's partnerships with ConcertAI and Caris Life Sciences for clinical AI.

AbbVie operates as a global matrix organization, combining therapeutic-area business units (Immunology, Neuroscience, Oncology, Aesthetics) with centralized functional organizations (Commercial, R&D, Operations, Finance, Legal, Strategy). Allergan Aesthetics is run as a semi-autonomous business unit within AbbVie, preserving the direct-to-physician commercial model and brand architecture that drove its success under Allergan ownership. The unit's Irvine, California campus functions as an operational hub with its own P&L and marketing budget.

AbbVie operates in 170+ countries but concentrates executive decision-making authority at the North Chicago, Illinois headquarters and key R&D sites in Cambridge, Massachusetts; Redwood City, California; and Ludwigshafen, Germany. As headcount has grown to approximately 60,000, AbbVie has invested heavily in enterprise platforms — including the Salesforce Life Sciences Cloud commercial rollout across 70+ countries and AI-enabled clinical analytics via ConcertAI — to support global coordination and standardized commercial execution at scale.